Conclusion: The anti-BCMA CAR T cell therapy bb2121 has demonstrated substantial activity in heavily pre-treated patients with multiple myeloma (MM). Updated results from 43 patients after five more months of follow-up show that bb2121 remains generally well-tolerated while inducing deep and durable responses in patients with advanced MM. The median PFS among 18 patients treated with active doses in the dose escalation cohort was 11.8 months and a 96% ORR was reported in 22 patients treated with >150 × 106 CAR T cells. Additionally, an unprecedented rate of MRD negativity was observed, with 100% of 16 evaluable responders achieving MRD negativity. Comparable activity was observed in patients with low (<50%) versus high (≥50%) BCMA-expressing myeloma (ORR of 100% vs 91%, respectively). Results from this ongoing study are informing the global pivotal phase II trial (KarMMaTM) in patients with relapsed and refractory MM, which is now open for enrollment in North America and Europe. MAIN SLIDES

Conclusion: Six cycles of BEACOPP provide a better long-term disease control than ABVD in advanced Hodgkin lymphoma but is associated to more frequent hematological toxicity and a higher risk of myelodysplasia/acute leukemia and infertility. The AHL2011 demonstrate that a de-escalation treatment with a switch from BEACOPP to ABVD is possible after two cycles of BEACOPP in most patients (84%) who reached a negative PET2 maintaining the same level of disease control and drastically reducing the risk of the treatment toxicity compared to patients who received the standard six cycles of BEACOPP. So, without any new drug, this approach based on the early response assessment using functional imaging (PET) improve the management of patients with advanced Hodgkin lymphoma, providing a better balance tolerability/efficacy of BEACOPP-based treatment and a better patient outcome (5y-PFS>85% and 5y-OS>95%) than ABVD. MAIN SLIDES

Study findings:

• -  Support the use of obinutuzumab plus chlorambucil (G-Clb) as frontline therapy in patients with CLL and

  co-existing diseases.

• -  Suggest obinutuzumab as the preferred anti-CD20 antibody to be used for chlorambucil-based

  chemoimmunotherapy, but also for future combination regimens for CLL.

In summary, RELEVANCE is the first randomized phase III trial comparing R2 vs standard R-chemo, followed by rituximab maintenance, in previously untreated patients with FL. R2 and R-chemo showed similar efficacy with a different safety profile. These results show that R2, a novel immunomodulatory approach, is a potential first-line option for FL patients requiring treatment.  MAIN SLIDES

We conclude that different forms of iron accumulation in macrophages (RBCs versus free heme and iron) in different diseases, show opposite effects on inflammation. Our data suggest that molecules able to bind iron have a therapeutic benefit on these diseases, through the modulation of these processes. MAIN SLIDES